#ESC26: Novartis pushes ahead with its IL-6 inhibitor despite Novo’s failure

Summary

Novartis is initiating a Phase 3 trial of its anti-IL-6 antibody to evaluate whether it can prevent cardiovascular events in patients with elevated cardiovascular risk by reducing inflammation, continuing development despite a competitor's failure in this mechanism.